Home > Healthcare > Amino Acid Metabolism Disorders Treatment Market
Amino Acid Metabolism Disorders Treatment Market Size
Amino Acid Metabolism Disorders Treatment Market size is anticipated to garner appreciable gains between 2024 and 2032 driven by advancements in biotechnology and molecular genetics for improving the understanding of these disorders.
Amino acids comprise building blocks that combine to form proteins. A person with one of these disorders might experience trouble breaking down amino acids, resulting in the buildup of harmful substances in the human body, leading to serious and life-threatening health issues. With the higher prevalence of these issues, there is a rising demand for treatment options, further creating favorable prospects for the industry gains. Moreover, the significant rise in healthcare expenditure due to the improving economic landscape and consistent improvement in disposable incomes will also stimulate the industry revenue stream.
On the contrary, amino acid supplements are usually associated with high prices, and some of the medications and drug therapies for treating amino acid metabolism disorders lead to numerous side effects. This, in addition to the limited awareness about these health conditions may hamper market growth to some extent through 2032.
Amino Acid Metabolism Disorders Treatment Market Trends
The increasing incidence of genetic disorders affecting amino acid metabolism is expected to fuel the industry progression. Conditions like phenylketonuria (PKU), maple syrup urine disease (MSUD), and homocystinuria are on the rise, necessitating effective treatment options. As per the NCBI report from 2023, PKU is the most prevalent autosomal recessive Mendelian condition of amino acid metabolism, affecting around 0.45 million people worldwide. With genetic testing becoming more widespread and accurate, more cases are identified early, further driving the demand for treatments. Advances in personalized medicine and gene therapy to offer promising solutions for these disorders.
Amino Acid Metabolism Disorders Treatment Market Analysis
Based on product, the market from the carglumic acid segment is projected to witness high demand between 2024 and 2032. This is attributed to the escalating regulatory approvals for various carglumic acid-based drugs. Additionally, carglumic acid acts as a carbamoyl phosphate synthetase 1 (CPS1) activator for aiding the detoxification of ammonia. Robust ability in treating disorders, such as N-acetylglutamate synthase deficiency and propionic acidemia.
With respect to sales channel, the amino acid metabolism disorders treatment market share from the hospital pharmacies segment is expected to generate substantial revenue by 2032. These pharmacies typically stock an extensive number of specialized devices and provide medications to hospital inpatients. With the surging burden of genetic disorders and the increasing focus on managing rare genetic disorders, hospital pharmacies are offering a wide range of treatment options, including enzyme replacement therapies and specialized drugs. Advantages like expertise, accessibility to advanced treatments, and close collaboration with healthcare providers will also propel the segment expansion.
From regional perspective, the North America amino acid metabolism disorders treatment market is estimated to depict a lucrative growth rate through 2032 owing to an upsurge in R&D projects. With a robust regulatory framework supporting R&D activities, pharmaceutical companies are increasingly investing in novel therapies. Furthermore, improved diagnosis rates, growing healthcare expenditure, and favorable reimbursement policies are also converging to create a favorable landscape for market expansion in North America.
Amino Acid Metabolism Disorders Treatment Market Share
Leading players in the amino acid metabolism disorders treatment industry include-
- Civentichem
- Pfizer
- Merck KGaA
- AMINO GmbH
- GlaxoSmithKline plc
Key amino acid metabolism disorders treatment firms are focusing on continuous R&D of innovative therapies, and strategic collaborations to sustain the rising competition. They are also developing personalized treatments and enhancing the patient access to care for expanding market reach.
Amino Acid Metabolism Disorders Treatment Industry News
- In January 2023, the U.S. FDA approved Jnana Therapeutics' Investigational New medication (IND) application for JNT-517, a medication being developed to treat PKU.